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2915pacing (BivP). This LBBB substrate has been deﬁned
by (“strict”) electrocardiographic or echocardio-
graphic criteria.
Risumet al. (1) showed that echocardiographic LBBB
is independently associated with long-term survival
after BivP. The implicit assumptions are that: 1)
the echocardiographic criteria for LBBB is closely
aligned with the substrate that is amenable to
correction by BivP; 2) BivP was effective in reversing
the abnormal electro-mechanical activation; and
3) correction of the echocardiographic LBBB-
related electro-mechanical activation resulted in the
better outcomes in patients with echocardiographic
LBBB.
We have recently reported that baseline LBBB (by
the strict electrocardiographic criteria) and the
reversal of LBBB, as evidenced by reversal of elec-
trocardiographic activation pattern, was associated
with the most favorable clinical outcomes (2). Clinical
outcomes in patients with LBBB without correction
by BivP were comparable to patients with non-
LBBB, which supports electrocardiographic LBBB as
a substrate for BivP.
In this regard, it is not clear if the clinical
outcomes observed by Risum et al. (1) are due to
correction of the echocardiographic LBBB-related
electro-mechanical contraction abnormality by BivP,
or even worsening of the contraction pattern in
patients without echocardiographic LBBB. The clinical
outcomes in patients with/without echocardiographic
LBBB and with/without correction by BivP should
be examined to demonstrate the relevance of
echocardiographic LBBB as a (or perhaps the)
substrate for BivP.*Hoong Sern Lim, MD
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Rhythm 2015;11:2247–55.REPLY: Echocardiographic Substrate for
Biventricular PacingWe appreciate Dr. Lim’s interest in our recent paper (1).
We demonstrated that patients without typical left
bundle branch block (LBBB) contraction by echocar-
diography, despite LBBB by electrocardiography,
have more than a 3-fold risk of death, heart transplant,
or left ventricular assist device within 4 years after
cardiac resynchronization therapy (CRT) implantation
(1). We agree that it is an important point that CRT
results in correction of the echocardiographic LBBB-
related contraction abnormality but in some cases
may cause worsening of the contraction pattern.
Indeed, recent studies suggest that CRT can be
harmful (2). Our previous work supports that a
typical contraction pattern can be reversed by CRT
whereas other patterns cannot, in which case a poor
outcome can be expected (3). Furthermore, it is
evident that LBBB contraction and activation do not
always agree. Despite the presence of complete
LBBB-activation, scarring of the ventricle may
abolish typical LBBB contraction in which case there
is no mechanical substrate for CRT (4) and the
patient is unlikely to respond favorably (5). This is
part of the explanation why it can be important to
address mechanical contraction in selection of CRT
candidates and why we found identiﬁcation of
typical LBBB contraction by echocardiography to be
superior to strict LBBB criteria by ECG (1). We
welcome any publications that offer logical
descriptors of pathophysiology that relate electrical
to mechanical events in the heart. Such studies are
important to understand why some patients respond
to CRT and others do not.*Niels Risum, MD, PhD
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2015;8:e003744.Evaluating Statin Versus
Statin Plus Ezetimibe
for Coronary Plaque
RegressionTsujita et al. (1) reported the results of the PRECISE-
IVUS (Plaque Regression With Cholesterol Absorption
Inhibitor or Synthesis Inhibitor Evaluated by
Intravascular Ultrasound) trial which found that,
compared with standard statin monotherapy, the
combination of statin plus ezetimibe showed greater
coronary plaque regression in a secondary prevention
setting, and suggested that the clinical event risk
reduction in the IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial) (2)
might have been derived from the suppression effect
of coronary atherosclerotic development by dual
lipid lowering therapy. However, after 12 months of
follow-up in the PRECISE-IVUS trial (1) there have
been no differences in clinical events between the
two groups. Of note, in the similar population
enrolled in the IMPROVE-IT (2), with a follow-up
of 7 years, it has been shown that the truly
signiﬁcant event reductions, which led to the tiny
absolute beneﬁt in composite endpoint, of lowering
low-density lipoprotein cholesterol (LDL-C) with
ezetimibe added to simvastatin was driven by both
coronary revascularization (an endpoint notoriously
subject to preference that falsely inﬂates beneﬁts) (3)
and non-fatal myocardial infarction. Furthermore,
it was not mentioned how many myocardial
infarctions were procedure-related (2).
Indeed, loss of blinding to treatment allocation
might have probably occurred in the IMPROVE-IT (2)because dual lipid-lowering therapy predictably
greatly lowers LDL-C, and physicians who managed
the patients knew the lipid variables (4). Loss of
blinding might bias decisions about revascularization
procedures and, in the ezetimibe plus statin group,
loss of blinding could further result in fewer
myocardial infarctions secondary to these procedures
(5). The outcome least subject to bias is obviously
all-cause mortality. In the IMPROVE-IT, the striking
absence of beneﬁt in reducing deaths from any cause,
accompanied by the failure to reduce deaths from
cardiovascular cause and from coronary heart disease
in a high risk population, is worrying.
As practicing physicians, we would hesitate to
prescribe an expensive therapy which may lead, at
best, to few mm3 reduction in atheroma volume
without meaningful reductions in clinical events.*Luca Mascitelli, MD
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cet;380:18145.REPLY: Evaluating Statin Versus Statin Plus
Ezetimibe for Coronary Plaque RegressionWe have read with great interest the letter by Drs.
Mascitelli and Goldstein commenting on our recent
paper (1), in which we showed that the combination
of statin plus ezetimibe demonstrated greater
coronary plaque regression compared with statin
monotherapy. First of all, the PRECISE-IVUS (Plaque
Regression With Cholesterol Absorption Inhibitor
